Simon Messner

Engineering · Physical Sciences

18h-index4.7kcitations55works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

3D Printing in Biomedical Research(14), PARP inhibition in cancer therapy(10), Liver physiology and pathology(9), Pharmacogenetics and Drug Metabolism(6), Drug Transport and Resistance Mechanisms(6)

Publications55 total

Incorporating Patient Input into the Target Product Profile
Therapeutic Innovation & Regulatory Science·2025· 1 citedOpen Access
Data from Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1–Dependent Gene Expression
2023Open Access
Supplementary Figure S1 from Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1–Dependent Gene Expression
2023Open Access
Supplementary Figure S1 from Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1–Dependent Gene Expression
2023Open Access
Data from Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1–Dependent Gene Expression
2023Open Access
<scp>TET</scp> enzymes control antibody production and shape the mutational landscape in germinal centre B cells
FEBS Journal·2019· 46 citedOpen Access
Human 3D multicellular microtissues: An upgraded model for the in vitro mechanistic investigation of inflammation-associated drug toxicity
Toxicology Letters·2019· 22 citedOpen Access
A novel microtissue-based 3D human liver NASH model for drug discovery
Toxicology Letters·2018· 1 cited
Abstract LB-034: Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics
Cancer Research·2018
Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling
Clinical and Translational Science·2018· 15 citedOpen Access
PO-441 Characterisation of 3D patient-derived xenograft tumour microtissues for in vitro oncology drug development
ESMO Open·2018Open Access
Diseased human 3D microtissues as building blocks for complex metabolic in-vitro systems
Journal of Hepatology·2018
A novel microtissue-based 3D human liver NASH model for drug discovery
Journal of Hepatology·2018
Development and characterization of a novel microtissue-based 3D human liver fibrosis model for anti-fibrotic drug discovery
Journal of Hepatology·2018
Using 3D Microtissues for Identifying Mitochondrial Liabilities
2018
Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues
Applied In Vitro Toxicology·2017· 68 citedOpen Access
Application of 3D liver microtissues for assessment of drug-induced liver injury (DILI) and for studying liver steatosis
Toxicology Letters·2017
Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis
PLoS ONE·2017· 92 citedOpen Access
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Archives of Toxicology·2017· 304 citedOpen Access
Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072
Archives of Toxicology·2017· 43 cited
page 1 of 3Next →

Frequent Co-authors

Jens M. Kelm(12), Michael O. Hottiger(10), Wolfgang Moritz(10), Jens Kelm(6), Paul O. Hassa(6), K. Roessger(6), Michael Elser(5), Lubor Borsig(5), Süheda Erener(5), Taras Valovka(5), Stephan Sylvest Keller(5), Max Gassmann(5), Claudia Escher(4), Irina Agarkova(4), Monika Kijańska(4), Patrick Guye(4), Radina Kostadinova(4), David A. Fluri(4), Jan G. Hengstler(3), Yulia Butscheid(3)